Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Denis Jullien; Joerg C. Prinz; Frank O. Nestle

doi:10.1038/jid.2014.295

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Denis Jullien^*
, Joerg C. Prinz
, Frank O. Nestle

^*Corresponding author for this work

Dermatology

Kings Coll London, Kings College London, University of London, St Johns Inst Dermatol, Div Genet & Mol Med, Sch Med,Guys Hosp
University of Lyon
Ludwig Maximilian University of Munich

Research output: Contribution to journal › Literature review › peer-review

77 Citations (Scopus)

Abstract

A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of immunogenicity and the mechanisms by which it affects clinical outcomes. It also considers testing for innmunogenicity and how biologic therapy of psoriasis may be tailored on the basis of immunogenicity.

Original language	English
Pages (from-to)	31-38
Number of pages	8
Journal	Journal of Investigative Dermatology
Volume	135
Issue number	1
DOIs	https://doi.org/10.1038/jid.2014.295
Publication status	Published - Jan 2015

Keywords

RHEUMATOID-ARTHRITIS PATIENTS
ANTI-DRUG ANTIBODIES
LONG-TERM TREATMENT
CHRONIC INFLAMMATORY DISEASES
NECROSIS-FACTOR INHIBITORS
LOW-DOSE METHOTREXATE
DOUBLE-BLIND
CLINICAL-RESPONSE
INFLIXIMAB INDUCTION
PLAQUE PSORIASIS

Access to Document

10.1038/jid.2014.295

Cite this

@article{58cefedc75a04f9ea2ad64e534321527,

title = "Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes",

abstract = "A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of immunogenicity and the mechanisms by which it affects clinical outcomes. It also considers testing for innmunogenicity and how biologic therapy of psoriasis may be tailored on the basis of immunogenicity.",

keywords = "RHEUMATOID-ARTHRITIS PATIENTS, ANTI-DRUG ANTIBODIES, LONG-TERM TREATMENT, CHRONIC INFLAMMATORY DISEASES, NECROSIS-FACTOR INHIBITORS, LOW-DOSE METHOTREXATE, DOUBLE-BLIND, CLINICAL-RESPONSE, INFLIXIMAB INDUCTION, PLAQUE PSORIASIS",

author = "Denis Jullien and Prinz, \{Joerg C.\} and Nestle, \{Frank O.\}",

year = "2015",

month = jan,

doi = "10.1038/jid.2014.295",

language = "English",

volume = "135",

pages = "31--38",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Immunogenicity of Biotherapy Used in Psoriasis

T2 - The Science Behind the Scenes

AU - Jullien, Denis

AU - Prinz, Joerg C.

AU - Nestle, Frank O.

PY - 2015/1

Y1 - 2015/1

N2 - A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of immunogenicity and the mechanisms by which it affects clinical outcomes. It also considers testing for innmunogenicity and how biologic therapy of psoriasis may be tailored on the basis of immunogenicity.

AB - A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of immunogenicity and the mechanisms by which it affects clinical outcomes. It also considers testing for innmunogenicity and how biologic therapy of psoriasis may be tailored on the basis of immunogenicity.

KW - RHEUMATOID-ARTHRITIS PATIENTS

KW - ANTI-DRUG ANTIBODIES

KW - LONG-TERM TREATMENT

KW - CHRONIC INFLAMMATORY DISEASES

KW - NECROSIS-FACTOR INHIBITORS

KW - LOW-DOSE METHOTREXATE

KW - DOUBLE-BLIND

KW - CLINICAL-RESPONSE

KW - INFLIXIMAB INDUCTION

KW - PLAQUE PSORIASIS

U2 - 10.1038/jid.2014.295

DO - 10.1038/jid.2014.295

M3 - Literature review

SN - 0022-202X

VL - 135

SP - 31

EP - 38

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 1

ER -

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Abstract

Keywords

Access to Document

Fingerprint

Cite this